Moderna on Friday smashed third-quarter revenue and earnings estimates and hiked its outlook for full-year sales growth, as some of its newer products gain momentum and Covid vaccine revenue outperforms.
See more from the earnings report:
Moderna CEO Stephane Bancel said he believes the personalized mRNA cancer vaccine his company is developing with Merck & Co. will work in a variety of tumors, directly addressing a key issue shrouding the company’s future
Moderna CEO Stéphane Bancel calls the company’s cancer vaccine study with Merck a “landmark,” pointing to a 42% improvement compared with Keytruda alone.
Bancel says Moderna is now focused on filing the drug with the FDA and believes it could be approved next year